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Abstract Much of the literature describing the search
for agents that increase the life span of rodents was
found to suffer from confounds. One-hundred-six
studies, absent 20 contradictory melatonin studies, of
compounds or combinations of compounds were
reviewed. Only six studies reported both life span
extension and food consumption data, thereby ex-
cluding the potential effects of caloric restriction. Six
other studies reported life span extension without a
change in body weight. However, weight can be an
unreliable surrogate measure of caloric consumption.
Twenty studies reported that food consumption or
weight was unchanged, but it was unclear whether
these data were anecdotal or systematic. Twenty-nine
reported extended life span likely due to induced
caloric restriction. Thirty-six studies reported no effect
onlifespan, andthree a decrease.The remainingstudies
sufferfrommoreseriousconfounds.Thoughstillwidely
cited, studies showing life span extension using short-
lived or “enfeebled” rodents have not been shown to
predict longevity effects in long-lived animals. We
suggest improvements in experimental design that will
enhance the reliability of the rodent life span literature.
First, animals should receive measured quantities of
food and its consumption monitored, preferably daily,
andreported.Weightsshouldbemeasuredregularlyand
reported. Second, a genetically heterogeneous, long-
lived rodent should be utilized. Third, chemically
defined diets should be used. Fourth, a positive control
(e.g., a calorically restricted group) is highly desirable.
Fifth,drugdosagesshouldbechosenbasedonsurrogate
endpoints or accepted cross-species scaling factors.
These procedures should improve the reliability of the
scientific literature and accelerate the identification of
longevity and health span-enhancing agents.
Keywords Longevitytherapeutics.CRmimetics.
Geroprotectors.Healthspan.Lifespan.Longevity.
Drugdiscovery.Pharmaceuticaltesting
Introduction
There are presently no authentic longevity therapeu-
tics. Such compounds would intervene in the process
of aging to extend mean and/or maximum life span,
maintain physiological function, and mitigate the
onset and severity of a broad spectrum of age-
related diseases in mammals. Such drugs might
engage the pathways used by caloric, methionine,
and phenylalanine restriction, and the longevity-
enhancing mutations (reviewed in Spindler 2009).
The terms “CR mimetics” and “geroprotectors” have
been used to describe such compounds (Weindruch et
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1982; Lippman 1981). In this report, we will use the
general term “longevity therapeutics.”
While a full understanding of the mechanisms of
aging will greatly facilitate the development and
deployment of longevity therapeutics, drug discovery
and development have a long history of using
surrogate assays for identifying therapeutics, often
with little knowledge or understanding of the etiology
of the diseases for which the therapeutics were
intended (discussed in Spindler 2006). Indeed, most
of the medications currently in our armamentarium
were discovered using surrogate assays. Thus, the
development and refinement of surrogate assays for
longevity therapeutics should speed their identification.
There have been multiple methods used in the
attempt to identify such compounds. For example, we
and others have utilized genome-wide microarray
studies of treated mice to identify potential therapeu-
tics (Barger et al. 2008; Spindler and Dhahbi 2007;
Spindler and Mote 2007; Spindler 2006; Dhahbi et al.
2005; Corton et al. 2004). Another approach, which
will be discussed here, is the direct assays of
compounds for their effects on the life span of
rodents.
Longevity assays using genetically normal, healthy
rodents
In mice, a number of natural mutations, gene knock-
outs, and overexpressed transgenes are known to
extend longevity and increase health span (Selman et
al. 2008; Taguchi et al. 2007; Kurosu et al. 2005;
Holzenberger et al. 2003; Flurkey et al. 2001;
Coschigano et al. 2000; Zhou et al. 1997; Brown-
Borg et al. 1996). Thus, potential therapeutic targets
for life span extension exist in mammals. However,
no robustly effective, safe, and widely recognized
longevity therapeutics exist at present. The likely
reason that such drugs have not been identified is that
we have not mounted an effective search for them.
Life span studies in rodents have been used in this
search (Table 1 and Electronic supplementary material
(ESM) Table 1). More recently, this literature benefits
from the improved levels of hygiene used in animal
husbandry (e.g., see Sebesteny 1991). For example,
several older studies in Table 1 appear to report data
consistent with the presence of infectious agents in
the rodent colony (Ferder et al. 1993; LaBella and
Vivian 1978; Sperling et al. 1978). Despite these
improvements, the design and implementation of
rodent life span studies could be improved further.
Table 1 and ESM Table 1 summarize and evaluate
all of the rodent life span studies we found using
repeated key word searches of the online databases. In
ESM Table 1, under the heading “Evaluation,” we
present our evaluation of the study results. ESM
Table 1 presents 106 life span studies performed with
healthy rodents. We excluded from this table 20
rodent life span studies performed with melatonin,
which are contradictory in their results and which
have been reviewed elsewhere (Anisimov et al. 2006).
Despite the fact that the effects of caloric restric-
tion on life span were described 76 years ago (McCay
et al. 1935), drug screening studies which regulate or
measure food consumption are rare. We found only
six studies which measured food consumption and
also found life span extension (Liang et al. 2010;
Caldeira da Silva et al. 2008; Cai et al. 2007; Stoll et
al. 1997; Yen and Knoll 1992; Cotzias et al. 1977).
These were deprenyl fed to Syrian hamsters (Stoll et
al. 1997); deprenyl and Dinh lang root extract fed to
mice (Yen and Knoll 1992); dinitrophenol fed to
normal mice of a short-lived strain (Caldeira da Silva
et al. 2008); L-dopa fed to male mice (Cotzias et al.
1977); marine collagen peptides fed to Sprague–
Dawley rats (Liang et al. 2010); and reduced
advanced glycation end product-containing standard
mouse diet fed to mice (Cai et al. 2007). These are the
only studies in the literature showing an increase in
rodent longevity for which the potential effects of
“voluntary” CR on life span can be confidently
excluded. Four studies which controlled or measured
caloric intake found no change in life span with
various treatments (Smith et al. 2010; Spindler and
Mote 2007; Lee et al. 2004; Pugh et al. 1999b).
Six other studies found life span extension and
reported the effects of the treatments on body weight
as a surrogate measure of food consumption (Table 1
and ESM Table 1). However, there are demonstrated
instances in which a discordance was found between
body weight and food consumption, making body
weight a potentially unreliable surrogate measure of
caloric consumption (see below). These treatments
are: coenzyme Q10 administered orally to male
Wistar rats fed a diet high in polyunsaturated fatty
acids (Quiles et al. 2004); Ginkgo biloba extract
112 AGE (2012) 34:111–120administered orally to male F344 rats (Winter 1998);
green tea polyphenols administered in drinking water
to male C57BL/6 (B6) mice (Kitani et al. 2007); 2-
mercaptoethanol administered orally in food to male
BC3F1 mice (Heidrick et al. 1984); PBN fed to B6
male mice (Saito et al. 1998); and piperoxane
administered by injection to F344 rats (Compton et
al. 1995).
Twenty studies found extended life span, but
potential CR effects cannot be excluded based on
the data available (Table 1 and ESM Table 1). Many
of these reports include statements to the effect that
no change in body weight (most common) or food
intake (rarely) occurred, but no data or analysis are
shown. No indication is given of whether the data
were anecdotal or systematic, when and how many
times during the study the measurements were taken,
or what statistical methods were used to analyze the
data. These uncertainties, coupled with the potential
fallibility of weight as a biomarker for food consump-
tion (see below), make these studies less persuasive.
Twenty-nine other studies report life span exten-
sion by treatments, but the body weight and/or food
consumption data presented in the publication suggest
that induced voluntary CR was responsible for the
longevity effects observed. Of the remaining studies,
nine would be difficult to repeat because the
composition, preparation, or mode of delivery of the
Table 1 Summary appraisal of the published life span studies using healthy rodents
106 separate life span studies where compounds were administered to normal
a rodents (less 20 contradictory melatonin studies)
b
6 studies found life span extension and showed food consumption was not responsible by measuring it
Deprenyl administered orally to female hamsters
Deprenyl and Dinh lang root extract administered to mice
Dinitrophenol administered to a short-lived, normal mouse strain
L-dopa administered orally to male mice
Marine collagen peptides extended the mean life span of Sprague–Dawley rats
Reduced advanced glycation end products present in standard rodent diet
6 studies found life span extension and reported no change in weight, with data shown or details given (this list excludes studies which
showed no change in food consumption listed above)
Coenzyme Q10 administered orally to male Wistar rats a diet high in polyunsaturated fatty acids
Ginkgo biloba administered orally to F344 rats
Green tea polyphenols administered orally to mice
2-Mercaptoethanol administered orally to mice
PBN administered orally to mice
Piperoxane administered by injection to rats
20 studies report LS extension but potential CR effects cannot be excluded
Body weight and/or food consumption called “unchanged”, but no data given or data given but not analyzed statistically (e.g., it
remains unclear whether the data are anecdotal or systematic, when and how many times during the study measurements were
taken, the means and standard deviations of the measurements, and what statistical methods were used to analyze the data?)
29 studies report results that are likely due to induced “voluntary” CR
Body weights or food consumption were less than those of controls or neither was reported
36 studies report no effect on life span
3 studies report reduced LS
9 studies would be difficult to repeat or have methodological or reporting confounds that render their data of uncertain significance
Only English language publications were reviewed
bNormal in this context means the animals had no known genetic defect leading to an artificially decreased life span and were not
given a physical or chemical treatment to stress the animals and shorten their life span
bIf a publication reports the testing of a compound or compounds using more than one group of animals, each test was listed and
counted separately. If a compound was tested in more than one publication, these studies are counted separately. If a compound had
differential effects on the lifespan of mice of different strains in a single report, these effects were counted under multiple categories.
AGE (2012) 34:111–120 113treatment agents are published in difficult to obtain
journals or are not reported.
Food consumption should be measured
Body weight is often used in longevity studies as a
surrogate measure of caloric consumption (Table 1
and ESM Table 1). The vast majority of the studies
using body weight as a surrogate do not report the
methods used or the results obtained (ESM Table 1).
Thus, the reader cannot know whether the conclu-
sions drawn used systematic or anecdotal measures.
The number of animals weighed, the number of times
they were weighed, and the statistics used are not
reported. Such problems are evident in two reports
from the NIA Interventions Testing Program (NIH-
ITP; Harrison et al. 2009; Strong et al. 2008; Miller et
al. 2007). While the studies are unusually robust in
many aspects of experimental design, including large
cohorts of genetically heterogeneous mice of both
sexes tested at multiple sites, most of their reports
give no details regarding body weight measurements
(Harrison et al. 2009; Strong et al. 2008; Miller et al.
2007). Thus, NIH-ITP investigators have reported that
the same concentration of rapamycin fed to HET3
mice produced either no effect on body weight
(methods and data unspecified; Harrison et al. 2009)
or a 6% or 10% decrease in body weight (for females
and males, respectively; Miller et al. 2011). Thus, it is
possible that the mice in the first study experienced an
undetected reduction in body weight. It also is unclear
whether the reductions in body weight found in the
second study were due to reduced caloric intake.
Thus, “voluntary CR” may have played a role in the
longevity effects observed. While one may seek
further information from these investigators at this
time, our publications are likely to outlive us.
Body weight is an unreliable surrogate measure of
caloric intake. Both dietary L-dopa and dietary
dinitrophenol reduce body weight without changing
food consumption (Caldeira da Silva et al. 2008;
Cotzias et al. 1977). A drug-induced discordance
between body weight and food intake may not be
uncommon. We found five agents or combination of
agents that significantly decreased body weight and
four agents or combination of agents which signifi-
cantly increased the body weight of mice fed
isocalorically (unpublished results). For example,
mice fed food supplemented with four doses of
nordihydroguaiaretic acid (NDGA) experienced an
approximately dose-responsive decrease in body
weight without a corresponding decrease in food
consumption (Fig. 1). Food was packed in 1-g pellets
and fed daily. Food intake for each of these groups was
carefully monitored and recorded. Any uneaten food,
even when masticated and dropped into the bedding,
was readily identifiable by shape, color, and texture.
Quantitatively, the group fed the highest dose of
NDGA weighed the same or less than a 20% calorie-
restricted (20% CR) group at most times during the
study (Fig. 1). Others have reported, without showing
data, that mice consuming NDGA-supplemented diets
ad libitum have no change in body weight relative to
controls (Strong et al. 2008). Thus, it is possible that
the mice in this published study maintained their body
weight by increasing food consumption. Feeding
measured quantities of food and monitoring of its
consumption ensures that life span data are not
confounded by changes in caloric consumption. This
reduces the likelihood of CR-related changes in life
span (Merry 2002; Compton et al. 1995).
Monitoring of both food consumption and body
weight will identify instances in which a compound
produces a discordance between them. Drug-induced
changes in activity, metabolic rate, or intestinal
absorption of calories might lead to such a discor-
dance, which would not be detected by monitoring of
only body weight. Once detected, a discordance can
be investigated further using measurements of spon-
taneous activity, metabolic rate, and absorption of
calories (e.g., Westbrook et al. 2009; Adams et al.
2006). Thus, measured feeding coupled with body
weight monitoring is a much more robust approach to
life span studies than body weight monitoring alone.
Methods for isocaloric feeding
In the author’s experience, measuring food con-
sumption is less difficult and expensive than it is
sometimes assumed to be. In an ongoing longevity
study involving 2,400 mice, measured feeding is
~9% of total costs. To deliver a known amount of
food to each cage conveniently, we use the method
described by Weindruch and colleagues (Pugh et al.
1999a). The food (AIN-93M) and any additional
components are cold-packed into 1-g pellets by Bio-
114 AGE (2012) 34:111–120Serv (Frenchtown, NJ). These round pellets are
conveniently scooped into a 1.6-cm inner diameter
Plexiglas tube fitted with a commercially available
plastic cap. Tubes cut to different lengths are used to
deliver different numbers of pellets to the cages.
If a supplemented diet is under-consumed, flavoring
can be added, the supplement can be changed to an
agentwithsimilaractions,thesupplementconcentration
in the food can be reduced, or, if desired, the amount of
food given to a control group can be decreased tothatof
the test agent. We slightly underfeed all the mice in our
studies to insure that all food is eaten.
Healthy, long-lived rodents, such as an F1 hybrid
or a more genetically heterogeneous mouse
should be used for compound screening
During our survey of the literature, we found many
reports of life span-based compound screening per-
formed with short-lived or enfeebled rodents (data not
shown). By “enfeebled,” we mean natural or selected
rodent lines that have genetic (or possibly epigenetic)
changes that reduce longevity and health relative to
their unaltered parental or control strains. For exam-
ple, many studies utilized senescence-accelerated
prone mouse strains (SAMP1 through SAMP9) to
rapidly screen for longevity therapeutics (Rodriguez
et al. 2008; Li et al. 2007; Umezawa et al. 2000;
Boldyrev et al. 1999; Kumari et al. 1997; Edamatsu et
al. 1995; Zhang et al. 1994). SAMP mice suffer from
the early onset of a spectrum of age-related patholo-
gies which abbreviate their life span. We found only
one study in which the effectiveness of an agent was
tested in both an SAMP mouse (SAMP8) and in one
of its associated control mouse strains (SAMPR1;
Fig. 1 Isocaloric feeding of diets containing NDGA reduced
body weight without altering food consumption. The left axis
shows the mean bimonthly weights of dietary groups fed AIN-
93M diet with no additional additives (empty square) or AIN-
93M diet containing NDGA at 1.5-g/kg diet (empty triangle),
2.5 g/kg diet (empty diamond), 3.5-g/kg diet (empty hexagon),
and 4.5-g/kg diet ( ); a 20% CR diet (empty downturned
triangle); or a 40% CR diet (circle). The mice were shifted
from chow feeding to the defined diets at 12 months of age.
The right axis shows the percentage of the kilocalories fed to
each group of mice which were actually consumed for the
group fed AIN-93M diet with no additives (filled square); AIN-
93M diet containing NDGA at 1.5-g/kg diet (filled triangle),
2.5-g/kg diet (filled diamond), 3.5-g/kg diet (filled hexagon),
and 4.5-g/kg diet ( ); a 20% CR diet (filled downturned
triangle); or a 40% CR diet (filled circle). The symbols
representing food consumption are superimposed in the figure,
making them difficult to distinguish because the mice ate
essentially all their food. Error bars and symbols for statistical
significance were omitted for the sake of clarity. The body
weights were significantly different than controls, as judged by
the non-parametric Mann–Whitney test, for the NDGA 1.5-g/kg
diet group at 22 months (P<0.01), 24 months (P<0.001),
26 months (P<0.01), 28 months (P<0.05), and 30 months (P<
0.01); for the 2.5-mg/kg diet group at 18 months (P<0.01), 20–
26 months (P<0.001), and 28 months (P<0.01); for the 3.5-
mg/kg diet group at 20 and 22 months (P<0.01), 24 and
26 months (P<0.001), and 28 and 30 months (P<0.01); and for
the 4.5-mg/kg diet group at 16 months (P<0.01) and 18–
30 months (P<0.001). The mice were shifted from chow
feeding to the defined diets at 12 months of age. These studies
used male B6C3F1 mice (Harlan Breeders, Indianapolis)
randomly assigned to treatment groups at 3 weeks of age. At
12 months of age, the mice were shifted from ad libitum chow
feeding (Diet no. 5001, Purina Mills, Richmond, IN) to daily
feeding with either 13.3 kcal/day per mouse of control diet
(AIN-93M, Diet no. F05312; Bioserv, Frenchtown, NJ) or daily
feeding with an identical quantity of control diet supplemented
with the indicated concentrations of NDGA. The 20% CR
group was shifted from ad libitum chow feeding to 11 kcal/day
per mouse of AIN-93M 20% Restricted Diet (Diet no. F06298,
Bioserv). The 40% CR group was shifted from ad libitum chow
feeding to 11 kcal/day per mouse of AIN-93M 20% Restricted
Diet for 2 weeks and thereafter to 7.46 kcal/day of AIN-93M
40% Restricted Diet (Diet no. F05314, Bioserv). The diets for
the 20% and 40% calorically restricted groups were fortified so
the mice received fewer calories in the form of carbohydrate
than the other groups, but approximately equal amounts of fat,
protein, vitamins, and minerals. All mice were fed the amounts
indicated daily. Food consumption was monitored at the time of
feeding, and any food left was noted and removed. With rare
exceptions, all food was eaten each day. The drugs were mixed
with powered diet and cold-pressed into 1-g pellets by Bio-serv.
The food was stored moisture free at 4°C until used. The mice
drank acidified (pH 4.0) tap water ad libitum and were
maintained on a 12-h light/dark cycle at 22°C. Cohorts of 296
negative control mice and 36 CR and treated mice were utilized
AGE (2012) 34:111–120 115Zhang et al. 1994). In this study, a botanical which
extend the life span of SAMP8 mice did not extend the
life span of the control strain. Similarly, resveratrol was
reported to extend the life span of high fat-fed, obese,
and diabetic mice (Baur et al. 2006). While this article
has been cited by many as evidence that resveratrol can
extend mammalian life span, the results did not
translate to healthy mice (Pearson et al. 2008). Thus,
screening agents in enfeebled rodents has not yet been
shown to facilitate the identification of compounds
which extend the life span of healthy animals.
For these reasons, studies designed to identify
longevity therapeutics should utilize long-lived mice,
such as an F1 hybrid or more genetically heteroge-
neous mouse. F1 hybrid mice, which are widely
available, are genetically heterozygous at all loci for
which their parents are heteroallelic. They are more
disease- and stress-resistant and have larger litters and
longer life spans than their inbred parental lines
(Flurkey et al. 2009). HET3 mice, which are produced
using a four-way crossbreeding scheme, are more
genetically heterogeneous than F1 mice and are used
by the NIH-ITP. However, they are more difficult to
produce and have shorter life spans than some F1
mice. For example, B6C3F1 mice have a mean life
span of about 915 days (Spindler and Mote 2007;
Pugh et al. 1999b; Smith and Walford 1977), while
HET3 mice have a mean life span of about 800 days
(Strong et al. 2008). Longer life spans are usually
regarded as signs of greater vigor. Outbred mice,
which are even more genetically heterogeneous than
HET3 mice, are more vigorous and less expensive
than inbred mice (Flurkey et al. 2009). However, they
have the disadvantage of being genetically undefined.
Because each mouse is genetically unique, study
results can be more varied and thus more difficult to
reproduce.
Chemically defined diets should be used
for gerontological research
There are three general categories of rodent diets:
cereal-based (non-purified), purified, and chemical-
l yd e f i n e d( K o z u le ta l .2008;R e e v e se ta l .1993;
American Institute of Nutrition ad hoc Committee on
Standards for Nutritional Studies 1977). The major-
ity of the studies summarized in ESM Table 1
appeared to have used non-purified or purified
cereal-based diets. However, cereal-based diets are
often variable in composition (American Institute of
Nutrition ad hoc Committee on Standards for
Nutritional Studies 1977), and this variability, and
the presence of trace contaminants, can strongly
influence experimental results (Kozul et al. 2008;
Jensen and Ritskes-Hoitinga 2007; Allred et al.
2004; Thigpen et al. 2004, 2003). For example,
Prolab-RMH 1000 rodent chow contains appreciable
quantities of polychlorinated dibenzo-p-dioxins and
dibenzofurans, probably from pesticide residues
(Schecter et al. 1996). Purina Laboratory Rodent
diet 5001 (LRD-5001) contains high concentrations
of methylmercury and a mixture of inorganic and
organic arsenic compounds at a concentration 36
times the EPA-recommended level for drinking
water (Kozul et al. 2008; Weiss et al. 2005). The
specifications for diets such as NIH-31 allow
manufacturers to use any of a number of sources of
protein, including fish meal, a possible source of
arsenic and other contaminants, or soy, a possible
source of pesticide residue. Thus, purified, defined
diets are preferable.
Use of a positive control is highly desirable
Many life span studies are published without the
benefit of a positive control group, such as a 40% CR
group. If none of the compounds tested in a study
extend life span, the possibility cannot be excluded
that the rodents would not respond to a longevity
treatment under the study conditions. Few reviewers
would endorse the publication of negative biochem-
ical data without the inclusion of a positive control to
show that the assay was working. This should be
similarly important for rodent life span studies.
Dosages of agents tested in rodents
The dosages at which potential therapeutics are tested
in rodents must balance a number of competing
theoretical and practical issues. Ideally, one would
like to know that a therapeutic level of the agent is
maintained throughout a life span study. Of course,
the ideal therapeutic level of an agent is not known
for most life span studies. Furthermore, food intake,
body volume, intestinal absorption, and metabolism
116 AGE (2012) 34:111–120may change with age. Monitoring the blood levels of
an agent throughout a life span study would be
difficult and expensive. Group sizes which would
make rodents available for testing throughout the
study are often impractical.
Several approaches can mitigate these limitations.
Published studies withwell-definedtreatmentendpoints
can be used to estimate dosages. In this way, one can be
reasonably certain that a therapeutic level of the agent is
achieved. Initial signs that a dosage is too high, such as
reduced food intake or inattention to grooming, can be
used to adjust dosages “on the fly.” Where rodent
studies cannot be found, equivalent rodent dosages can
be calculated from human dosages using default cross-
species scaling factors (Reagan-Shaw et al. 2008;U S
EPA 2005; Rhomberg and Lewandowski 2004;D o u r -
son et al. 1992, 1996; Dourson and Stara 1983). These
scaling factors are often used to set and access drug
dosages in human and animal studies (e.g., Chalastanis
et al. 2010). Empirically, small animals have been
found to require larger dosages per gram body weight
than larger animals. These differences are due to
pharmacokinetic differences (e.g., rates of uptake,
metabolism, and clearance of compounds) and to
pharmacodynamic differences (e.g., rates of damage
to macromolecules, cellular repair and regeneration,
signaling cascades, and proliferative responses) be-
tween small and large animals. One widely used
scaling formula increases the human dosage in milli-
grams per kilogram body weight/day by tenfold to
obtain the equivalent mouse dosage. Another scaling
factor also in use is based on the 3/4 power of body
weight [i.e., (milligrams/kilogram body weight)
3/4/
day], which leads to equivalent mouse dosages that
are about sevenfold higher than the equivalent human
dosages. While these calculations were initially devel-
oped for chemotherapeutics, they are also used as
starting points when human dosages must be extrapo-
lated from preclinical rodent data (Chalastanis et al.
2010).
Summary: the preferred design for testing
potential longevity therapeutics using mouse life
span studies
B a s e do nt h ei n f o r m a t i o nr e v i e w e da b o v e ,w e
recommend a number of design parameters essential
or highly desirable for rodent life span assays: (1) The
diets should be fed in measured amounts and
consumption monitored. Body weight should be
monitored regularly. These measurements and their
statistical analysis should be reported. (2) A long-
lived, healthy rodent strain should be used, preferably
an F1 or further outcrossed strain. (3) Chemically
defined diets should be used. They ensure the greatest
degree of reproducibility and avoid the confounds
introduced by contaminants or compositional vari-
ability. (4) Use of a positive control is highly
desirable. Without a positive control, negative results
are of questionable significance. We use a 40% CR
control, which also allows us to calibrate the effects of
a treatment (e.g., Fig. 1). (5) Dosages can be chosen
using treatment endpoints gleaned from the literature
or, where necessary, from human dosages using
accepted cross-species scaling factors. Use of these
methods will produce a more reliable literature on
which to base further studies.
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